1. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14: 354–377.
2. Abraham C, Cho JH. Inflammatory Bowel Disease. N Engl J Med 2009; 361: 2066–2078.
3. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661–678.
4. Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39: 207–211.
5. Massey DC, Parkes M. Common pathways in Crohn’s disease and other inflammatory diseases revealed by genomics. Gut 2007; 56: 1489–1492.
6. Rioux JD, Xavier RJ, Taylor KD et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39: 596–604.
7. Van Limbergen J, Wilson DC, Satsanagi J. The genetics of Crohn’s disease. Annu Rev Genomics Hum Genet 2009; 10: 89–116.
8. Molodecky NA, Kaplan GG. Environmental Risk Factors for Inflammatory Bowel Disease. Gastroenterol Hepatol 2010; 6: 339–346.
9. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627–1640.
10. Rutgeerts P, Goboes K, Peeters M et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991; 338: 771–774.
11. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620–1633.
12. Chassaing B, Rolhion N, de Vallé A et al. Crohn disease – associated adherent-invasive E. coli bacteria target mouse and human Peyer’s patches via long polar fimbriae. J Clin Invest 2011; 121: 966–997.
13. Henderson P, Van Limbergen JE, Schwarze J et al. Function of intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 382–395.
14. Gaudier E, Hoebler C. Physiological role of mucins in the colonic barrier integrity. Gastroenterol Clin Biol 2006; 30: 965–974.
15. Ramasundara M, Leach ST, Lemberg DA et al. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 2009; 24: 202–208.
16. Wehkamp J, Stange EF, Fellermann K. Defensin-immunology in inflammatory bowel disease. Gastroenterologie Clin Biol 2009; 33 (Suppl 3): 137–144.
17. Kyd JM, Cripps AW. Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine 2008; 26: 6221–6224.
18. Ismail AS, Behrendt CL, Hooper LV. Reciprocal interactions between commensal bacteria and gamma delta intraepithelial lymphocytes during mucosal injury. J Immunol 2009; 182: 3047–3054.
19. Yoshida M, Claypool SM, Wagner JS et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004; 20: 769–778.
20. Marchesi J, Shanahan F. The Normal intestinal microbiota. Curr Opin Infect Dis 2007; 20: 508–513.
21. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inlammatory bowel disease. Nature 2007; 448: 427–434.
22. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411: 599–603.
23. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411: 603–606.
24. Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem 2003; 278: 5509–5512.
25. Abraham C, Cho JH. Functional consequence of NOD2 (CARD15) mutations. Inflamm Bowel Dis 2006; 12: 641–650.
26. Tanabe T, Chamaillard M, Oqura Y et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J 2004; 23: 1587–1597.
27. Lees CW, Sastsanagi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol 2009; 3: 513–534.
28. van Heel DA, Ghosh S, Butler M et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn’s disease. Lancet 2005; 365: 1794–1796.
29. Wehkamp J, Salzman NH, Porter E et al. Reduced Paneth cell α-defensins in ileal Crohn’s disease. Proc Natl Acad Sci USA 2005; 102: 18129–18134.
30. Wehkamp J, Wang G, Kübler I et al. The Paneth cell alpha-defensin deficiency of ileal Crohn’s disease is linked to Wnt/Tcf-4. J Immunol 2007; 179: 3109–3118.
31. Wehkamp J, Stange EF, Fellermann K. Defensin-immunology in inflammatory bowel disease. Gastroenterologie Clin Biol 2009; 33 (Suppl 3): 137–144.
32. Sartor RB. Does Mycobacterium avium subspecies paratuberculosis cause Crohn’s disease? Gut 2005; 54: 896–898.
33. Coulombe F, Divangahi M, Veyrier F et al. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med 2009; 206: 1709–1716.
34. Rahman MK, Midtling EH, Svingen PA et al. The Pathogen Recognition Receptor NOD2 Regulates Human FOXP3+ T Cell Survival. J Immunol 2010; 184: 7247–7256.
35. Jess T, Riis L, Jespersgaard C et al. Disease concordance, zygosity, and NOD2/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. Am J Gastroenterol 2005; 100: 2486–2492.
36. Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology 2007; 133: 1327–1339.
37. Hradsky O, Lenicek M, Dusatkova P et al. Variants of CARD15, TNFA and PTPN22 and susceptibility to Crohn’s disease in the Czech population: high frequency of the CARD15 1007fs. Tissue Antigens 2008; 71: 538–547.
38. Lesage S, Zouali H, Cézard JP et al. EPWG-IBD Group; EPIMAD Group; GETAID Group. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845–857.
39. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229–241.
40. Yamamoto-Furusho JK, Podolsky DK. Innate immunity in inflammatory bowel disease. World J Gastroenterol 2007; 13: 5577.
41. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010–7017.
42. González-Navajas JM, Fine S, Law J et al. TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice. J Clin Invest 2010; 120: 570–581.
43. Browning BL, Huebner C, Petermann I et al. Has Toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 2007; 102: 2504–2512.
44. Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187–191.
45. Ferwerda B, McCall MB, Alonso S et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 2007; 104: 16645–16650.
46. Watanabe T, Kitani A, Murray PJ et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5: 800–808.
47. Kullberg BJ, Ferwerda G, De Jong DJ et al. Crohn’s disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology 2008; 123: 600–605.
48. Schmitd D, Dengjel J, Schoor O et al. Autophagy in innate and adaptive immunity against intracellular pathogens. J Mol Med 2006; 84: 194–202.
49. Homer CR, Richmond AL, Rebert NA et al. ATG16L1 and NOD2 Interact in an Autophagy-Dependent Antibacterial Pathway Implicated in Crohn’s Disease Pathogenesis. Gastroenterology 2010; 139: 1630–1641.
50. Kuballa P, Huett A, Rioux JD et al. Impaired autophagy of an intracellular pathogen induced by a Crohn’s disease associated ATG16L1 variant. PLoS One 2008; 3: e3391.
51. Saitoh T, Fujita N, Jang MH et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456: 264–268.
52. Cadwell K, Liu JY, Brown SL et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008; 456: 259–263.
53. Hussey S, Travassos LH, Jones NL. Autophagy as an emerging dimension of adaptive and innate immunity. Semin Immunol 2009; 21: 233–241.
54. Parronchi P, Romagnani P, Annunziato F et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn’s disease. Am J Pathol 1997; 150: 823–832.
55. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461–1463.
56. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950–957.
57. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 2009; 58: 1152–1167.
58. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715–725.
59. Sandborn WJ, Feagan BG, Fedorak RN et al. Ustekinumab Crohn’s Disease Study Group. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008; 135: 1130–1141.
60. Monteleone I, Pallone F, Monteleone G. Interleukin-23 and Th17 Cells in the Control of Gut Inflammation. Mediators Inflamm 2009; 2009: 297645.
61. Andoh A, Zhang Z, Inatomi O et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005; 129: 969–984.
62. Monteleone G, Caruso R, Fina D et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006; 55: 1774–1780.
63. Liang SC, Tan XY, Luxenberg DP et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271–2279.
64. Dambacher J, Beigel F, Zitzmann K et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 2009; 58: 1207–1217.
65. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nat Immunol 2008; 9: 641–649.
66. Xu L, Kitani A, Fuss I et al. Cutting edge: regulatory T cells induce CD4+CD25−Foxp3− T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 2007; 178: 6725–6729.
67. Laurence A, Tato CM, Davidson TS et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26: 371–381.